![]() ![]() Please see your health care professional for more information about your specific medical condition and the use of this drug. A common side effect is a skin condition called radiation dermatitis, also known as X-ray dermatitis or radiation burns. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Call your doctor right away if you notice any of these side effects: Allergic reaction: Itching or hives, swelling in your face or hands, swelling or tingling. It is not a substitute for medical advice. Radium-223 dichloride is a radioactive drug which goes to the source of cancer bone pain and may alleviate pain associated with bone metastasis. Important: The drug information on this page is meant to be educational. Radiopharmaceuticals: Radiation Therapy Enters the Molecular Age Clinical Trials Accepting Patientsįind Clinical Trials for Radium Ra 223 Dichloride - Check for trials from NCI's list of cancer clinical trials now accepting patients. Is also being studied in the treatment of other types ofÄefinition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug. Male and female partners should use effective birth control while taking Xofigo. Common side effects of Xofigo include nausea, vomiting, diarrhea, swelling of the arms or legs, and low blood cell counts. It is used in patients whose cancer has metastasized (spread) to the bones and is causing symptoms but has not spread to other organs. Xofigo (radium Ra 223) is a radioactive cancer medication used to treat male patients with symptoms of advanced prostate cancer that has spread to the bones. Patients who receive any type of radiation therapy (external beam or brachytherapy) to treat their prostate cancer can have side effects. Figure shows tumor cell killing by therapeutic radiopharmaceutical. But unlike hair loss during chemotherapy, it only causes hair loss in the area being treated. Clinical utility and activity of therapeutic radiopharmaceuticals for prostate cancer and bone metastases 25, 31, 33, 34, 35, 36, 37. Hair loss is a common side effect of radiotherapy. Prostate cancer that is castrate resistant (has not responded to treatments that lower testosterone levels). There were side effects in the form of xerostomia, bone marrow toxicity, and renal impairment 31, 32.FDA label information for this drug is available at DailyMed. ![]()
0 Comments
Leave a Reply. |